Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Optimal dose of losartan for renoprotection in diabetic nephropathy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Adrenal insufficiency in kidney transplant patients during low-dose prednisolone therapy: a cross-sectional case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Angiotensin II subtype-1 receptor antagonists represent a valuable new class of drugs in the treatment of diabetic nephropathy. The aim of our study was to evaluate the optimal dose of losartan for renoprotection and blood pressure reduction in diabetic nephropathy.

METHODS: Fifty consecutive hypertensive type 1 diabetic patients with diabetic nephropathy received increasing doses of losartan, 50, 100, and 150 mg once daily in three periods each lasting 2 months. At baseline and at the end of each treatment period, albuminuria, 24-h blood pressure (TM2420 A&D), and glomerular filtration rate (GFR) ([(51)Cr]EDTA plasma clearance) were determined.

RESULTS: Baseline values of albuminuria (geometric mean (95% CI)) and GFR (means+/-SEM) were 1138 (904-1432) mg/24 h and 91+/-3 ml/min/1.73 m(2), respectively. The blood pressure at baseline was 155/81+/-3/2 mmHg. All doses of losartan reduced albuminuria and blood pressure. Albuminuria was reduced by 30% (95% CI (15-41)) on losartan 50 mg, 48% (35-57) by losartan 100 mg, and 44% (32-56) by losartan 150 mg (all P values <0.01 vs baseline). Losartan 100 mg daily was significantly more effective than 50 mg daily in reducing albuminuria (P<0.01) without differences between the two high doses. Losartan 50, 100, and 150 mg daily decreased systolic/diastolic blood pressures by 7/4, 12/6, and 10/5 mmHg, respectively (all P<0.05). Losartan 100 mg daily was more effective than 50 mg daily in reducing systolic, diastolic, and mean arterial blood pressure (P=0.05), without differences between the high doses. Treatment with losartan 100 and 150 mg lowered GFR by 4 ml/min/1.73 m(2) (P<0.05).

CONCLUSION: Our study suggests that the optimal dose of losartan is 100 mg daily for renoprotection and blood pressure reduction in type 1 diabetic patients with diabetic nephropathy.

Original languageEnglish
JournalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Volume17
Issue number8
Pages (from-to)1413-8
Number of pages6
ISSN0931-0509
Publication statusPublished - Aug 2002

    Research areas

  • Albuminuria, Antihypertensive Agents, Blood Pressure, Diabetic Angiopathies, Diabetic Nephropathies, Diastole, Dose-Response Relationship, Drug, Glomerular Filtration Rate, Humans, Hypertension, Kidney, Losartan, Systole, Time Factors, Journal Article, Research Support, Non-U.S. Gov't

ID: 52020962